Physician profile
Jan Thompson
NPI 1801169123
$2,267.09
in general payments reported to CMS, 2019-2025
13 companies · $949 in 2025
The $949 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $29.57 · 2022: $269 · 2023: $474 · 2024: $545 · 2025: $949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,968.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $719.34 | 2022-2025 | Fetroja |
| Gilead Sciences, INC. | $542.10 | 2022-2025 | Yeztugo, Veklury |
| La Jolla Pharmaceutical Company | $274.97 | 2022-2024 | Xerava |
| Viiv Healthcare Company | $268.14 | 2025 | Dovato, Rukobia |
| Abbvie INC. | $122.80 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $104.99 | 2023 | Camzyos |
| Merck Sharp & Dohme LLC | $68.69 | 2022-2024 | Dificid, Recarbrio, Zerbaxa |
| Cumberland Pharmaceuticals, INC. | $51.54 | 2024 | Vibativ |
| Melinta Therapeutics, LLC | $37.48 | 2022-2025 | Orbactiv, Kimyrsa, Rezzayo |
| Astellas Pharma US INC | $24.51 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $19.63 | 2025 | Vowst |
| Angiodynamics, INC. | $16.46 | 2023 | Angiovac |
| Biomerieux INC | $16.44 | 2025 | Filmarray Torch Module |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jan Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.